12:00 AM
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

UX001: Interim Phase II data

Interim 24-week data from a 48-week, double-blind, U.S. and Israeli Phase II trial in 47 patients ages 18-65 years showed that once-daily 3 and 6 mg UX001 for 24 weeks led to dose-dependent improvement in muscle strength in some muscle groups, particularly in the upper extremities at the 6 mg dose, vs. placebo. Ultragenyx...

Read the full 250 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >